Alnuctamab
Highest phase reached
Phase 3
Drug type
Antibody
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Antibody
- Drug name
- Alnuctamab
- alnuctamab
- Alnuctamab
- alnuctamab [INN]
- ALNUCTAMAB [USAN]
- Alnuctamab [WHO-DD]
- alnuctamab inn
- alnuctamab usan
- alnuctamab who dd
- immunoglobulin g1 kappa lambda with domain crossover anti homo sapiens tnfrsf17 tnf receptor superfamily member 17 tumor necrosis factor receptor superfamily member 17 b cell maturation antigen bcma bcm tnfrsf13a cd269 and anti homo sapiens cd3e cd3 epsilon leu 4 monoclonal antibody bispecific trivalent
- IMMUNOGLOBULIN G1-KAPPA/LAMBDA WITH DOMAIN CROSSOVER, ANTI-(HOMO SAPIENS TNFRSF17 (TNF RECEPTOR SUPERFAMILY MEMBER 17, TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 17, B CELL MATURATION ANTIGEN, BCMA, BCM, TNFRSF13A, CD269)) AND ANTI-(HOMO SAPIENS CD3E (CD3 EPSILON, LEU-4)), MONOCLONAL ANTIBODY, BISPECIFIC, TRIVALENT
- CAS registry numbers
- 2296827-07-9
- ChEMBL ID
- CHEMBL6068570
- FDA ingredient codes (UNII)
- 7OSV6M6T4D
- Patents
- 0
- Designations
- 1
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Drug name stem
- -mab
Investigated indications
- Condition
- Multiple Myeloma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0001378
- Subject identifier
- D009101
- Condition identifier
- EFO_0001378
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0007915
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0009693
- Highest recorded phase
- 3
- NCT06121843
- NCT06163898
- NCT06232707
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (4)
- A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma
- A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
- Alnuctamab for Refractory SLE (LATTE Study)
In development for (2)
- Plasma cell myeloma Phase 3
- Systemic lupus erythematosus Phase 1